Evolent Health to Release Q1 2026 Financial Results on May 7
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy EVH?
Source: PRnewswire
- Earnings Release Schedule: Evolent Health is set to announce its Q1 2026 financial results on May 7, 2026, before the market opens, which is expected to provide investors with critical financial data and operational performance insights.
- Conference Call Details: Following the earnings release, Evolent will host a conference call at 8 a.m. ET, where investors can participate by dialing 855.940.9467 or 412.317.6034 for international calls, ensuring to call 15 minutes prior for questions.
- Live Broadcast and Playback: The conference call will be broadcast live on Evolent's investor relations website, and an audio playback will be available for 90 days post-call, allowing investors who missed the live event to catch up on the discussion.
- Company Overview: Evolent Health specializes in achieving better health outcomes for individuals with complex conditions, aiming to transform healthcare delivery through proven solutions that simplify and reduce costs, serving a national base of leading payers and providers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EVH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EVH
Wall Street analysts forecast EVH stock price to rise
14 Analyst Rating
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.540
Low
5.00
Averages
9.33
High
16.00
Current: 2.540
Low
5.00
Averages
9.33
High
16.00
About EVH
Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Evolent Health to Release Q1 2026 Financial Results on May 7
- Earnings Release Schedule: Evolent Health is set to announce its Q1 2026 financial results on May 7, 2026, before the market opens, which is expected to provide investors with critical financial data and operational performance insights.
- Conference Call Details: Following the earnings release, Evolent will host a conference call at 8 a.m. ET, where investors can participate by dialing 855.940.9467 or 412.317.6034 for international calls, ensuring to call 15 minutes prior for questions.
- Live Broadcast and Playback: The conference call will be broadcast live on Evolent's investor relations website, and an audio playback will be available for 90 days post-call, allowing investors who missed the live event to catch up on the discussion.
- Company Overview: Evolent Health specializes in achieving better health outcomes for individuals with complex conditions, aiming to transform healthcare delivery through proven solutions that simplify and reduce costs, serving a national base of leading payers and providers.
See More
Global X Uranium ETF Underperforms Today
- ETF Performance: The Global X Uranium ETF is down approximately 2.6% in Tuesday afternoon trading, indicating a weak performance that may undermine investor confidence in the uranium market.
- Weak Individual Stocks: Among the ETF's components, shares of Nano Nuclear Energy fell by about 9.6%, while Centrus Energy dropped by approximately 7.5%, suggesting a bearish sentiment surrounding these companies that could lead to capital outflows.
- Market Impact Analysis: The decline in the uranium ETF may reflect investor concerns about the nuclear energy sector's outlook, particularly in the context of global energy transitions, potentially influencing future investment decisions.
- Investor Sentiment Shift: As the uranium ETF underperforms, investors may reassess their allocations to nuclear-related assets, leading to increased market volatility and impacting overall investment strategies.
See More
Evolent Health Appoints New Chief Product Officer
- Leadership Change: Evolent Health has appointed Archie Mayani as Chief Product Officer, bringing over 20 years of leadership experience in health tech and AI, which is expected to accelerate the company's product strategy.
- Innovative Background: Prior to joining Evolent, Mayani served as CPO at GHX, where she pioneered AI-driven capabilities to enhance the resilience of the global healthcare supply chain, providing valuable experience for Evolent's product innovation.
- Performance Enhancement: At Change Healthcare, Mayani focused on innovations in clinical decision support and revenue cycle platforms, helping to reduce administrative burdens for providers and payers, which is anticipated to improve Evolent's product efficiency and market competitiveness.
- Industry Recognition: Mayani has received multiple industry awards, including the Inspiring Leader Award at the 2023 Health 2.0 conference, showcasing her influence and leadership in the healthcare sector, which will enhance Evolent's industry reputation.
See More
Foodsmart Appoints New Board Member to Advance Foodcare in Medicaid
- New Board Member: Foodsmart has appointed Dr. Toyin Ajayi, co-founder and CEO of Cityblock Health, to its Board of Directors, bringing extensive value-based care experience that is expected to drive growth in the Medicaid sector.
- Integration of Nutrition Care: Ajayi emphasizes the critical role of nutrition support within healthcare systems, as Foodsmart aims to improve health outcomes and reduce overall costs for over 3 million members by integrating nutrition care with medical services.
- Advancing Health Equity: Ajayi's appointment will enhance Foodsmart's impact on Medicaid and high-need populations, promoting health equity and ensuring that patients with complex medical needs have access to essential nutrition support.
- Industry Recognition: Ajayi's leadership and innovative models in value-based care have garnered widespread recognition, and her experience will provide valuable strategic guidance for Foodsmart to stand out in a competitive market.
See More
EVOLENT HEALTH: OPPENHEIMER LOWERS PRICE TARGET FROM $12 TO $6
- Stock Price Adjustment: Evolent Health has reduced its target price from $12 to $6.
- Market Impact: This significant cut in target price may reflect changes in market conditions or company performance.
See More
Evolent Health to Participate in Investor Conferences
- Executive Participation: Evolent Health's executive management team will participate in upcoming investor conferences, aiming to enhance the company's transparency and trust in the capital markets through direct interaction with investors.
- Webcast Availability: The events will feature live audio webcasts and replays, allowing investors to access relevant information via Evolent's investor relations website, ensuring timely communication and broad outreach.
- Company Mission: Evolent specializes in achieving better health outcomes for individuals with complex conditions through solutions that simplify and reduce healthcare costs, thereby enhancing its competitive position in the healthcare industry.
- Industry Recognition: Evolent is consistently recognized as one of the top places to work in healthcare nationally, demonstrating its success in attracting and retaining talent, which further solidifies its leadership in the healthcare services sector.
See More
Evolent Health to Release Q1 2026 Financial Results on May 7
- Earnings Release Schedule: Evolent Health is set to announce its Q1 2026 financial results on May 7, 2026, before the market opens, which is expected to provide investors with critical financial data and operational performance insights.
- Conference Call Details: Following the earnings release, Evolent will host a conference call at 8 a.m. ET, where investors can participate by dialing 855.940.9467 or 412.317.6034 for international calls, ensuring to call 15 minutes prior for questions.
- Live Broadcast and Playback: The conference call will be broadcast live on Evolent's investor relations website, and an audio playback will be available for 90 days post-call, allowing investors who missed the live event to catch up on the discussion.
- Company Overview: Evolent Health specializes in achieving better health outcomes for individuals with complex conditions, aiming to transform healthcare delivery through proven solutions that simplify and reduce costs, serving a national base of leading payers and providers.
See More
Global X Uranium ETF Underperforms Today
- ETF Performance: The Global X Uranium ETF is down approximately 2.6% in Tuesday afternoon trading, indicating a weak performance that may undermine investor confidence in the uranium market.
- Weak Individual Stocks: Among the ETF's components, shares of Nano Nuclear Energy fell by about 9.6%, while Centrus Energy dropped by approximately 7.5%, suggesting a bearish sentiment surrounding these companies that could lead to capital outflows.
- Market Impact Analysis: The decline in the uranium ETF may reflect investor concerns about the nuclear energy sector's outlook, particularly in the context of global energy transitions, potentially influencing future investment decisions.
- Investor Sentiment Shift: As the uranium ETF underperforms, investors may reassess their allocations to nuclear-related assets, leading to increased market volatility and impacting overall investment strategies.
See More
Evolent Health Appoints New Chief Product Officer
- Leadership Change: Evolent Health has appointed Archie Mayani as Chief Product Officer, bringing over 20 years of leadership experience in health tech and AI, which is expected to accelerate the company's product strategy.
- Innovative Background: Prior to joining Evolent, Mayani served as CPO at GHX, where she pioneered AI-driven capabilities to enhance the resilience of the global healthcare supply chain, providing valuable experience for Evolent's product innovation.
- Performance Enhancement: At Change Healthcare, Mayani focused on innovations in clinical decision support and revenue cycle platforms, helping to reduce administrative burdens for providers and payers, which is anticipated to improve Evolent's product efficiency and market competitiveness.
- Industry Recognition: Mayani has received multiple industry awards, including the Inspiring Leader Award at the 2023 Health 2.0 conference, showcasing her influence and leadership in the healthcare sector, which will enhance Evolent's industry reputation.
See More
Foodsmart Appoints New Board Member to Advance Foodcare in Medicaid
- New Board Member: Foodsmart has appointed Dr. Toyin Ajayi, co-founder and CEO of Cityblock Health, to its Board of Directors, bringing extensive value-based care experience that is expected to drive growth in the Medicaid sector.
- Integration of Nutrition Care: Ajayi emphasizes the critical role of nutrition support within healthcare systems, as Foodsmart aims to improve health outcomes and reduce overall costs for over 3 million members by integrating nutrition care with medical services.
- Advancing Health Equity: Ajayi's appointment will enhance Foodsmart's impact on Medicaid and high-need populations, promoting health equity and ensuring that patients with complex medical needs have access to essential nutrition support.
- Industry Recognition: Ajayi's leadership and innovative models in value-based care have garnered widespread recognition, and her experience will provide valuable strategic guidance for Foodsmart to stand out in a competitive market.
See More
EVOLENT HEALTH: OPPENHEIMER LOWERS PRICE TARGET FROM $12 TO $6
- Stock Price Adjustment: Evolent Health has reduced its target price from $12 to $6.
- Market Impact: This significant cut in target price may reflect changes in market conditions or company performance.
See More
Evolent Health to Participate in Investor Conferences
- Executive Participation: Evolent Health's executive management team will participate in upcoming investor conferences, aiming to enhance the company's transparency and trust in the capital markets through direct interaction with investors.
- Webcast Availability: The events will feature live audio webcasts and replays, allowing investors to access relevant information via Evolent's investor relations website, ensuring timely communication and broad outreach.
- Company Mission: Evolent specializes in achieving better health outcomes for individuals with complex conditions through solutions that simplify and reduce healthcare costs, thereby enhancing its competitive position in the healthcare industry.
- Industry Recognition: Evolent is consistently recognized as one of the top places to work in healthcare nationally, demonstrating its success in attracting and retaining talent, which further solidifies its leadership in the healthcare services sector.
See More
